Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.
Schwartzberg L, Navari RM, Ruddy KJ, LeBlanc TW, Clark-Snow R, Wickham R, Kloth D, Binder G, Bailey WL, Turini M, Potluri R, Liu X, Papademetriou E, Roeland EJ. Schwartzberg L, et al. Among authors: potluri r. Support Care Cancer. 2023 Oct 25;31(12):654. doi: 10.1007/s00520-023-08119-1. Support Care Cancer. 2023. PMID: 37878086 Free PMC article.
Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
Zeidan AM, Pollyea DA, Borate U, Vasconcelos A, Potluri R, Rotter D, Kiendrebeogo Z, Gaugler L, Prebet T, Strocchia M, Bonifacio G, Chen C. Zeidan AM, et al. Among authors: potluri r. Ann Hematol. 2023 Aug;102(8):2299. doi: 10.1007/s00277-023-05327-x. Ann Hematol. 2023. PMID: 37341779 Free PMC article. No abstract available.
Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.
Usmani S, Ahmadi T, Ng Y, Lam A, Desai A, Potluri R, Mehra M. Usmani S, et al. Among authors: potluri r. Oncologist. 2016 Nov;21(11):1355-1361. doi: 10.1634/theoncologist.2016-0104. Epub 2016 Aug 2. Oncologist. 2016. PMID: 27486203 Free PMC article.
Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
Zeidan AM, Pollyea DA, Borate U, Vasconcelos A, Potluri R, Rotter D, Kiendrebeogo Z, Gaugler L, Prebet T, Strocchia M, Bonifacio G, Chen C. Zeidan AM, et al. Among authors: potluri r. Ann Hematol. 2023 Apr;102(4):749-754. doi: 10.1007/s00277-023-05109-5. Epub 2023 Feb 3. Ann Hematol. 2023. PMID: 36732419 Free PMC article.
104 results